Evidence map›Paper›PMID 41798922›Full record

ArticleFrontiers in immunology2026

Integrating pleural PD-1

Weizhen Jiang, Leilei Lv, Yaoxin Zhang, Qiuxia Qu, Cheng Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Weizhen JiangDepartment of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Leilei LvDepartment of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yaoxin ZhangDepartment of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Qiuxia QuClinical Immunology Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, China.
Cheng ChenDepartment of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC), particularly in lung adenocarcinoma, and is associated with poor prognosis. A better understanding of the role of PD-1 Methods: We performed a cohort study involving NSCLC patients with MPE. The abundance of pleural PD-1 Results: We found that PD-1 Discussion: The combination of pleural PD-1

Indexed as

Adenocarcinoma of LungCD8-Positive T-LymphocytesLung NeoplasmsPleural Effusion, MalignantProgrammed Cell Death 1 ReceptorAgedB7-H1 AntigenCarcinoma, Non-Small-Cell LungErbB ReceptorsFemaleHumansMaleMiddle AgedMutationPrognosisB7-H1 AntigenErbB ReceptorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorCD8+ T cellLENT scoremalignant pleural effusionPD-1prognosis

Identifiers

PMID41798922
PMCPMC12960558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.